Pfizer Inc. warned doctors on Friday that one of its bestselling painkillers, Bextra, might increase the risk of a heart attack or stroke in coronary artery bypass surgery patients.
An initial study last year raised similar concerns in the same kinds of patients.
Merck's decision to withdraw Vioxx cast suspicion on the safety of drugs in that class.
Pfizer's warning is sure to fuel the debate about the overall safety of these drugs for all patients.
Regulators have indicated plans to review COX-2 drugs.
